As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...

Sure, I wee like Austin Powers and the number twos are like tennis balls – get comfortable with that idea. But I’m the best ...

As global shortages hit Ozempic and Wegovy, rivals like Eli Lilly gain ground, including in India’s growing market for ...

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...

We came across a bullish thesis on The Cigna Group (CI) on Antonio Linares’ Substack. In this article, we will summarize the ...

Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy. Then it smashed into roadblocks - shortages that led Novo to limit demand by ...

Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.